NASDAQ: SWTX
Springworks Therapeutics Inc Stock

$57.43-1.16 (-1.98%)
Updated Feb 14, 2025
SWTX Price
$57.43
Fair Value Price
$2.48
Market Cap
$4.27B
52 Week Low
$28.21
52 Week High
$60.00
P/E
-14.76x
P/B
8.02x
P/S
17.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$135.49M
Earnings
-$275.16M
Gross Margin
94.5%
Operating Margin
-203.09%
Profit Margin
-203.1%
Debt to Equity
0.14
Operating Cash Flow
-$209M
Beta
1.13
Next Earnings
Feb 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A

SWTX Overview

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SWTX's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
B
Growth
C
Momentum
C
Sentiment
D
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
SWTX
Ranked
#89 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important SWTX news, forecast changes, insider trades & much more!

SWTX News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SWTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SWTX ($57.43) is overvalued by 2,218.42% relative to our estimate of its Fair Value price of $2.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SWTX ($57.43) is not significantly undervalued (2,218.42%) relative to our estimate of its Fair Value price of $2.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SWTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SWTX due diligence checks available for Premium users.

Valuation

SWTX fair value

Fair Value of SWTX stock based on Discounted Cash Flow (DCF)

Price
$57.43
Fair Value
$2.48
Overvalued by
2,218.42%
SWTX ($57.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SWTX ($57.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SWTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SWTX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-14.76x
Industry
-169.22x
Market
37.92x

SWTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
8.02x
Industry
4.77x
SWTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SWTX's financial health

Profit margin

Revenue
$49.3M
Net Income
-$53.5M
Profit Margin
-108.6%
SWTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SWTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$608.9M
Liabilities
$76.3M
Debt to equity
0.14
SWTX's short-term assets ($435.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SWTX's short-term assets ($435.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SWTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SWTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$25.4M
Investing
$28.6M
Financing
$1.3M
SWTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SWTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SWTXC$4.27B-1.98%-14.76x8.02x
CRSPC$4.26B+14.33%-11.46x2.21x
BHVNF$4.19B-0.86%-4.40x13.26x
KRYSC$4.41B-1.61%83.28x4.98x
PTCTB$4.00B+4.33%-8.72x-3.79x

Springworks Therapeutics Stock FAQ

What is Springworks Therapeutics's quote symbol?

(NASDAQ: SWTX) Springworks Therapeutics trades on the NASDAQ under the ticker symbol SWTX. Springworks Therapeutics stock quotes can also be displayed as NASDAQ: SWTX.

If you're new to stock investing, here's how to buy Springworks Therapeutics stock.

What is the 52 week high and low for Springworks Therapeutics (NASDAQ: SWTX)?

(NASDAQ: SWTX) Springworks Therapeutics's 52-week high was $60.00, and its 52-week low was $28.21. It is currently -4.28% from its 52-week high and 103.58% from its 52-week low.

How much is Springworks Therapeutics stock worth today?

(NASDAQ: SWTX) Springworks Therapeutics currently has 74,386,403 outstanding shares. With Springworks Therapeutics stock trading at $57.43 per share, the total value of Springworks Therapeutics stock (market capitalization) is $4.27B.

Springworks Therapeutics stock was originally listed at a price of $23.85 in Sep 13, 2019. If you had invested in Springworks Therapeutics stock at $23.85, your return over the last 5 years would have been 140.8%, for an annualized return of 19.21% (not including any dividends or dividend reinvestments).

How much is Springworks Therapeutics's stock price per share?

(NASDAQ: SWTX) Springworks Therapeutics stock price per share is $57.43 today (as of Feb 14, 2025).

What is Springworks Therapeutics's Market Cap?

(NASDAQ: SWTX) Springworks Therapeutics's market cap is $4.27B, as of Feb 16, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Springworks Therapeutics's market cap is calculated by multiplying SWTX's current stock price of $57.43 by SWTX's total outstanding shares of 74,386,403.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.